Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.

Edouard JanuelJérôme De SezePatrick VermerschElisabeth MaillartBertrand BourreJulie PiqueElisabeth MaillartCaroline BensaXavier MoissetJean PelletierSandra Vukusic Bertrand AudoinCéline Louaprenull null

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)

These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.

Keyphrases

coronavirus disease
end stage renal disease
sars cov
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
multiple sclerosis
mass spectrometry
ms ms
patient reported